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Supplementary Material 1: PRISMA 2009 check-list 
 
Section/topic 
Item 
No Checklist item 
Reported on 
page No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, 
interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review 
registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 3 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study 
design (PICOS) 
3 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information 
including registration number 
None 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication 
status) used as criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the 
search and date last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated Supplementary 
Material 3 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-
analysis) 
Methods 
Data collection process 10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis 
Methods 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) for 
each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies) Methods 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre- Methods 
Section/topic 
Item 
No Checklist item 
Reported on 
page No 
specified 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with 
a flow diagram 
Figure 1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). Table 1 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect 
estimates and confidence intervals, ideally with a forest plot 
Results and Figure 
2 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Results and Figure 
2 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see item 16) Not applicable 
Discussion 
Summary of evidence 24 Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as 
health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, 
reporting bias) 
Discussion 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research Discussion 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic 
review 
None 
Supplementary Material 2: MOOSE checklist  
 
Statins and secondary prevention of venous thromboembolism: pooled analysis of 
published observational cohort studies 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
√ Problem definition There have been suggestions that statins may have a potential role in 
secondary prevention of venous thromboembolism (VTE), but the 
evidence is inconsistent 
√ Hypothesis statement Statins may have a role in the secondary prevention of VTE 
√ Description of study outcomes VTE [which includes deep vein thrombosis (DVT) and pulmonary 
embolism (PE)] 
√ Type of exposure  Statin use 
√ Type of study designs used Prospective (cohort, case-cohort or “nested case control”) population-
based studies 
√ Study population Populations with prior VTE  
Reporting of search strategy should 
include 
 
√ Qualifications of searchers Setor Kunutsor, MD PhD; Samuel Seidu, MD 
√ Search strategy, including time 
period included in the synthesis and 
keywords 
Time period: from inception of MEDLINE, EMBASE, Web of 
Science to January 25, 2017.  
Search strategy: 
Supplementary Material 3 
 
√ Databases and registries searched MEDLINE, EMBASE, and Web of Science 
√ Search software used, name and 
version, including special features 
Ovid was used to search EMBASE 
Endnote used to manage references  
√ Use of hand searching We searched bibliographies of retrieved papers  
√ List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  
The citation list for excluded studies is available upon request. 
√ Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language 
√ Method of handling abstracts and 
unpublished studies 
None found 
√ Description of any contact with 
authors 
Not applicable 
Reporting of methods should include  
√ Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be 
tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
√ Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, exposure, outcome, and 
possible effect modifiers of the association. 
√ Assessment of confounding We assessed confounding by ranking individual studies on the basis 
of different adjustment levels, and performed sub-group analyses to 
evaluate differences in the overall estimates according to levels of 
adjustment. 
√ Assessment of study quality, 
including blinding of quality 
assessors; stratification or regression 
on possible predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa 
Scale using pre-defined criteria namely: population 
representativeness, comparability (adjustment of confounders), 
ascertainment of outcome.  
√ Assessment of heterogeneity Heterogeneity of the studies was explored with I2 statistic that 
provides the relative amount of variance of the summary effect due to 
the between-study heterogeneity. 
√ Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses is detailed in the methods. 
We performed Knapp-Hartung as well as the DerSimonian–Laird 
random effects meta-analysis with Stata 14. 
√ Provision of appropriate tables and 
graphics 
Table 1, Figures 1 and 2 
Reporting of results should include  
√ Graph summarizing individual study 
estimates and overall estimate 
Figure 2 
√ Table giving descriptive information 
for each study included 
Table 1  
√ Results of sensitivity testing 
 
Sensitivity analysis was conducted to assess the influence of each 
individual study by omitting one study at a time and calculating a 
pooled estimate for the remainder of the studies. Results section 
√ Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates, 
I2 values and results of sensitivity analyses 
Reporting of discussion should include  
√ Quantitative assessment of bias Inability to assess publication bias due to the limited number of 
studies. Limitations have been discussed. 
 
√ Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria 
in methods section. 
√ Assessment of quality of included 
studies 
Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
√ Consideration of alternative 
explanations for observed results 
Discussed in the context of the results. 
√ Generalization of the conclusions Discussed in the context of the results. 
√ Guidelines for future research Well-designed intervention studies are needed to corroborate these 
findings. 
√ Disclosure of funding source No separate funding was necessary for the undertaking of this 
systematic review. 
Supplementary Material 3: MEDLINE literature search strategy from 1946 to present 
 
Relevant studies, published before January 25, 2017 (date last searched), were identified through 
electronic searches not limited to the English language using MEDLINE, EMBASE, and the Science 
Citation Index databases. Electronic searches were supplemented by scanning reference lists of articles 
identified for all relevant studies (including review articles), by hand searching of relevant journals and 
by correspondence with study investigators. The computer-based searches combined search terms 
related to statins and venous thromboembolism without language restriction. 
 
1     exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ (38526) 
2     statins.mp. (25447) 
3     exp Thromboembolism/ (55621) 
4     recurrent venous thromboembolism.mp. (829) 
5     VenousThrombosis.mp. (1) 
6     exp Venous Thromboembolism/ (7992) 
7     exp Pulmonary Embolism/ (39779) 
8     recurrent pulmonary embolism.mp. (522) 
9     recurrent deep vein thrombosis.mp. (192) 
10     3 or 4 or 5 or 6 or 7 or 8 or 9 (91733) 
11     1 or 2 (47480) 
12     10 and 11 (200) 
13     limit 12 to humans (181) 
 
Each part was specifically translated for searching alternative databases. 
 
 
